Several possible studies
Story checked
Omega-3 EPA linked to longer survival after surgery for colorectal cancer liver metastases (opens in a new tab)
medicalxpress.com · 2026-10-26
Short answer
Several possible studiesStudy not confirmed.
Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
Omega-3 EPA linked to longer survival after surgery for colorectal cancer liver metastases
medicalxpress.com · 2026-10-26
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Multiple potential source studies identified.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
View article claimsSearch result
Several studies could fit.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedPatients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo.View evidenceHide evidence
As statedlonger overall survival
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 6Not checkedThe results were from the phase 3 EMT2 trial presented at the ESMO Congress 2026.View evidenceHide evidence
As statedphase 3
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 6Not checkedThe randomized, double-blind, placebo-controlled EMT2 trial enrolled 418 patients scheduled for liver resection with curative intent at 13 U.K. hepatobiliary surgery centers and assigned them to 4 g daily of EPA (icosapent ethyl) or mineral oil placebo.View evidenceHide evidence
As stated418 patients; 4 g daily
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 6Not checkedEstimated five-year overall survival was 62.0% with EPA versus 45.1% with placebo, with a hazard ratio of 0.68 (95% CI 0.48–0.96; p=0.03).View evidenceHide evidence
As stated62.0% vs 45.1%; HR 0.68
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 5 of 6Not checkedMedian progression-free survival was similar in the two groups, and EPA was well tolerated with no excess adverse events, bleeding, or atrial fibrillation compared with placebo.View evidenceHide evidence
As statedmedian PFS 13.5 vs 12.9 months
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 6 of 6Not checkedLead author Mark Hull and outside expert Chiara Cremolini said the survival benefit is intriguing or clinically meaningful but that confirmatory results are likely needed before the treatment is incorporated into daily practice.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Europe PMC, Crossref · 15 candidate papers
Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol.
BMJ Open · 2023 · PubMed, Europe PMC
WITHDRAWN: Nomogram for predicting the overall survival for young-onset colorectal cancer with liver metastases: a SEER database analysis
2022 · Crossref
Antitumor Effect of 5-Fluorouracil-Loaded Liposomes Containing n-3 Polyunsaturated Fatty Acids in Two Different Colorectal Cancer Cell Lines.
AAPS PharmSciTech · 2021 · PubMed
PTH-106 Survival outcomes following hepatectomy for stage iv colorectal liver metastases: a comparison of liver- versus colon-first approach
Liver – Liver Cancer · 2015 · Crossref
An Endolichenic Fungi-Derived Fatty Acid, cis-10-Nonadecenoic acid, Suppresses Colorectal Cancer Stemness.
2025 · Europe PMC